[Budget impact analysis of idarucizumab for the management of patients treated with dabigatran in emergency / urgent situations in Italy]. Farmeconomia. Health Economics and Therapeutic Pathways, [S. l.], v. 17, n. 2, p. 47–58, 2016. DOI: 10.7175/fe.v17i2.1243. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/1243. Acesso em: 15 feb. 2026.